Novartis: FDA Accepts Xolair sBLA for Nasal Polyps

Date : 12/11/2019 @ 11:37AM
Source : Dow Jones News
Stock : Novartis AG (NVS)
Quote : 95.93  0.83 (0.87%) @ 12:59AM
After Hours
Last Trade
Last $ 95.93 ◊ 0.00 (0.00%)

Novartis: FDA Accepts Xolair sBLA for Nasal Polyps

Novartis (NYSE:NVS)
Historical Stock Chart

2 Months : From Nov 2019 to Jan 2020

Click Here for more Novartis Charts.

By Colin Kellaher


Novartis AG (NOVN.EB, NVS) on Wednesday said the U.S. Food and Drug Administration accepted the company's supplemental biologics license application for Xolair for the treatment of nasal polyps in adults with inadequate response to intranasal corticosteroids.

The Swiss drug make said it expects the agency to make a decision on the indication by the third quarter of 2020.

Novartis said Xolair, if approved, would be the first antibody to help reduce the size of nasal polyps and help improve symptoms through targeting and blocking immunoglobulin E.

Xolair is currently approved in the U.S. to treat of moderate to severe persistent allergic asthma and chronic idiopathic urticaria. Novartis and Roche Holdings AG's (ROG.EB) Genentech unit work together to develop and co-promote Xolair in the U.S.


Write to Colin Kellaher at


(END) Dow Jones Newswires

December 11, 2019 06:22 ET (11:22 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest NVS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.